Organisation paid for research Program year 2024 Source: CMS Open Payments

Cedar Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$274,284

12 payments

Through program year 2024, Cedar Clinical Research LLC is reported as receiving $274,284 in research payments, across 12 payments.

By program year

5 rows
Year Kind Amount Payments
2024 Research $47,163 2
2023 Research $18,937 1
2022 Research $47,452 3
2021 Research $125,547 3
2020 Research $35,184 3

Breakdown

Who paid Research payments · program years 2020–2024
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $274,284 12 payments
Studies the money was for Research payments · program years 2020–2024
  1. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $108,287 3 payments
  2. A Multicenter, Randomized, Flexible-Dose, Double Blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder $69,467 2 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post?Traumatic Stress Disorder $44,163 1 payment
  4. A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole $18,796 1 payment
  5. Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder $13,836 1 payment
  6. A Phase Iiib Multi-Center, Open-Label, Mirror-Image, Study in Adult Subjects With Schizophrenia Treated Prospectively for 6-Months With Abilify Mycite $9,700 1 payment
  7. A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Arm Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Drobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia $3,625 1 payment
  8. A Multicenter, Open-Label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Borderline Personality Disorder. $3,410 1 payment
  9. Amulticenter,Randomized,Double-Blind,Placebo-Controlled,Parallel-Armstudy Toassess Theefficacy,Safety, Andtolerability of Avp-786 (Deudextromethorphanhydrobromide [D6 Dm]/Quinidine Sulfate [Q]) for Thetreatment Ofnegativesymptoms Ofschizophrenia $3,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record